BioCentury | May 12, 2014
Company News

MorphoSys, Temple University deal

...that Temple can apply the technology. MorphoSys gained the technology from its 2010 acquisition of Sloning BioTechnology GmbH...
BioCentury | Mar 5, 2012
Company News

MorphoSys deal

...milestones and royalties. Details were not disclosed. MorphoSys gained the technology through its acquisition of Sloning BioTechnology GmbH...
BioCentury | Feb 27, 2012
Regulation

Vivus: Back for seconds

A beefed up REMS and clearer picture of the safety profile for obesity candidate Qnexa phentermine/topiramate allowed Vivus Inc. to score a positive vote at last week's FDA advisory panel meeting, but the other two...
BioCentury | Jan 30, 2012
Product Development

A more rational antibody platform

...With technology gained from its 2010 acquisition of Sloning BioTechnology GmbH, MorphoSys AG started from scratch to create...
...the library was built using the Slonomics platform, which MorphoSys gained through its acquisition of Sloning...
BioCentury | Jan 2, 2012
Company News

MorphoSys, Novozymes deal

...of the multi-year deal were not disclosed. MorphoSys gained the technology through its acquisition of Sloning BioTechnology GmbH...
BioCentury | Oct 17, 2011
Finance

Close to SBIR deal

Private companies with VC ownership of 50% or more finally may be able to access funds under the Small Business Innovation Research program. A compromise between House and Senate versions of an SBIR reauthorization bill...
BioCentury | Sep 26, 2011
Regulation

Obesity upswing

While much of the last year has been bad news for obesity companies, the swift application of the appeals process at FDA looks to have paid off for Orexigen Therapeutics Inc. and its obesity compound...
BioCentury | Aug 1, 2011
Company News

MorphoSys, Dana-Farber Cancer Institute deal

...research and diagnostic antibodies unit granted the institute rights to use Slonomics technology from MorphoSys' Sloning BioTechnology GmbH...
...from the deal. Terms were not disclosed. MorphoSys gained the technology through its acquisition of Sloning...
BioCentury | Dec 13, 2010
Company News

MorphoSys, Pfizer deal

...Pfizer's Rinat Neuroscience Corp. subsidiary received non-exclusive rights to use Slonomics technology from MorphoSys' Sloning BioTechnology GmbH subsidiary...
...Further financial terms were not disclosed. MorphoSys gained the technology through its October acquisition of Sloning...
BioCentury | Dec 11, 2010
Top Story

MorphoSys up on Pfizer deal, milestones

...is eligible for annual license fees. MorphoSys gained the technology through its October acquisition of Sloning BioTechnology GmbH...
Items per page:
1 - 10 of 19
BioCentury | May 12, 2014
Company News

MorphoSys, Temple University deal

...that Temple can apply the technology. MorphoSys gained the technology from its 2010 acquisition of Sloning BioTechnology GmbH...
BioCentury | Mar 5, 2012
Company News

MorphoSys deal

...milestones and royalties. Details were not disclosed. MorphoSys gained the technology through its acquisition of Sloning BioTechnology GmbH...
BioCentury | Feb 27, 2012
Regulation

Vivus: Back for seconds

A beefed up REMS and clearer picture of the safety profile for obesity candidate Qnexa phentermine/topiramate allowed Vivus Inc. to score a positive vote at last week's FDA advisory panel meeting, but the other two...
BioCentury | Jan 30, 2012
Product Development

A more rational antibody platform

...With technology gained from its 2010 acquisition of Sloning BioTechnology GmbH, MorphoSys AG started from scratch to create...
...the library was built using the Slonomics platform, which MorphoSys gained through its acquisition of Sloning...
BioCentury | Jan 2, 2012
Company News

MorphoSys, Novozymes deal

...of the multi-year deal were not disclosed. MorphoSys gained the technology through its acquisition of Sloning BioTechnology GmbH...
BioCentury | Oct 17, 2011
Finance

Close to SBIR deal

Private companies with VC ownership of 50% or more finally may be able to access funds under the Small Business Innovation Research program. A compromise between House and Senate versions of an SBIR reauthorization bill...
BioCentury | Sep 26, 2011
Regulation

Obesity upswing

While much of the last year has been bad news for obesity companies, the swift application of the appeals process at FDA looks to have paid off for Orexigen Therapeutics Inc. and its obesity compound...
BioCentury | Aug 1, 2011
Company News

MorphoSys, Dana-Farber Cancer Institute deal

...research and diagnostic antibodies unit granted the institute rights to use Slonomics technology from MorphoSys' Sloning BioTechnology GmbH...
...from the deal. Terms were not disclosed. MorphoSys gained the technology through its acquisition of Sloning...
BioCentury | Dec 13, 2010
Company News

MorphoSys, Pfizer deal

...Pfizer's Rinat Neuroscience Corp. subsidiary received non-exclusive rights to use Slonomics technology from MorphoSys' Sloning BioTechnology GmbH subsidiary...
...Further financial terms were not disclosed. MorphoSys gained the technology through its October acquisition of Sloning...
BioCentury | Dec 11, 2010
Top Story

MorphoSys up on Pfizer deal, milestones

...is eligible for annual license fees. MorphoSys gained the technology through its October acquisition of Sloning BioTechnology GmbH...
Items per page:
1 - 10 of 19